19-20 February, 2019 | San Diego

Enhancing the Sensitivity, Reliability and Standardization of Liquid Biopsies to Advance Clinical Utility and Industry Applications for Improved Patient Treatment and Monitoring

The 3rd Annual Precision LBx Summit will bring together pharmaceutical, biotech, academic and clinical leaders to provide a platform to advance the validation, clinical utility and industry applications of liquid biopsies.

Showcasing robust data-lead studies and trials, the meeting will tackle challenges in technology, regulation, reimbursement and standardization and sensitivity of tests. Exploring a multitude of biomarkers from CTCs and ctDNA to RNA and exosomes, Precision LBx 2019 will advance the industry applications of liquid biopsies for oncology and chronic disease through CSF, urine and plasma-derived biomarkers.

As the dedicated scientific and networking forum of liquid biopsy trailblazers, the meeting is here to help precision medicine leaders radically improve the analysis and clinical utility of liquid biopsies as clinical monitoring tools.

 


What 2018 Attendees Had to Say:

“Very well organized, with speakers covering a variety of expertise.” Senior Scientist, Adaptimmune

“Informative, enlightening, timely” Director, Biofluidica

“Educational, inspiring, well-organized” Senior Scientist, Genentech

“Informative, current, useful” Director, Pfizer

“Excellent, informative, interactive” Director, JWCI

“Inspiring, thought provoking, exciting” Oncology Fellow, Children’s Hospital Los Angeles